Tamer Mohamed told Cell & Gene Meeting on the Mesa that Aspect Biosystems plans to generate clinical data in 2027, and set out preclinical data for its adrenal insufficiency and type 1 diabetes programs.
Sartorius chief technology officer Oscar-Werner Reif told the Cell & Gene Meeting on the Mesa the company believes its automated Eveo platform can bring cell therapy costs below $40,000 per patient.
Stephen Ward, chief technology officer of the UK’s Cell and Gene Therapy Catapult, told Meeting on the Mesa that developers can share data, testbeds and manufacturing space without losing control.
CEO Hans Schambye told Cell & Gene Meeting on the Mesa that BOOST Pharma expects to be able to start a placebo-controlled trial of BT-101, its investigational stem cell therapy for osteogenesis imperfecta, in the middle of next year.
Tim Hunt told Cell & Gene Meeting on the Mesa that Wall Street data point to seven more cell and gene therapy blockbusters, and said ARM will soon announce changes to its membership dues.
Karim Mikhail told Cell & Gene Meeting on the Mesa the FDA wants eventually to bring its separate rare disease efforts into one package, and set out how the Expedited IND Pilot is meant to speed up first-in-human trials.
CEO Gaurav Shah said a product enriched for full capsids drove the dose cut in the pivotal Danon trial, ahead of an investor webinar on updated Phase 1 data on October 6.
CEO Devyn Smith presented preclinical data from gene editing programs for ALS, with a first CNS IND filing targeted for 2027.
The Vancouver immunologist on myeloid cells as a delivery route, STING for cold tumours, and why in vivo CAR could land near the price of a checkpoint inhibitor.
The Cambridge founder on re-engineering antibodies to break into solid tumours, raising a seed round without a professor behind her, and why hiring in the UK is her hardest problem.
CamMed CEO Dr. Ahmet Can Berkyurek on an AI-discovered, single-protein replicase drawn from biology's most ancient machinery — and his case for building it in the UK
Zidesamtinib produced responses in 44% of 117 patients who had already taken a ROS1 inhibitor, and in 48% of those with measurable brain metastases.
Enlicitide cut LDL-C by 56% against placebo in a 2,904-patient trial, putting PCSK9 inhibition into a once-daily tablet.
Gedatolisib plus fulvestrant and palbociclib reached 9.3 months median progression-free survival against 2.0 on fulvestrant alone.
Atacicept cut proteinuria by 42% against placebo at week 36, though accelerated approval leaves open whether it preserves kidney function.
New options emerged in MRI contrast imaging, complicated urinary tract infections, and thyroid eye disease.
